Assoc Prof Dr. Elcin Aydin | Endometrium Cancer | Best Researcher Award

Posted on by Pencis

Assoc Prof Dr. Elcin Aydin | Endometrium Cancer | Best Researcher Award

University of Health Sciences, Izmir | Turkey

AUTHOR PROFILE

Scopus

Orcid ID

EARLY ACADEMIC PURSUITS

  • Assoc Prof Dr. Elçin Aydın’s academic journey began with a strong foundation in medical sciences. She pursued her education with a focus on radiology, demonstrating a keen interest in the diagnostic and therapeutic applications of imaging technologies. Her early academic pursuits laid the groundwork for her specialization in abdominal and genitourinary radiology.

PROFESSIONAL ENDEAVORS

  • Dr. Aydın is currently affiliated with the University of Health Sciences in Izmir, Turkey, and works at Izmir City Hospital. Her professional endeavors have been marked by a commitment to clinical excellence and academic rigor. She has been an active member of prestigious organizations such as the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), the European Congress of Radiology (ECR), and the European Society of Urogenital Radiology (ESUR).

CONTRIBUTIONS AND RESEARCH FOCUS

  • Dr. Aydın has made significant contributions to the field of radiology through her research and clinical work. She has published 14 original articles in SCI-EXP indexed journals and authored 4 case studies, highlighting her expertise in abdominal and genitourinary radiology. Her research focuses on the diagnostic accuracy and clinical applications of imaging techniques in these areas, aiming to improve patient outcomes through advanced radiological practices.

IMPACT AND INFLUENCE

  • Through her scholarly publications and clinical practice, Dr. Aydın has had a considerable impact on the field of radiology. Her work is frequently cited by peers, reflecting the influence of her research on contemporary radiological practices. Her involvement in ESGAR, ECR, and ESUR underscores her influence within the radiological community, where she contributes to the advancement of knowledge and practice standards.

ACADEMIC CITATIONS

  • Dr. Aydın’s research has garnered significant academic attention, with numerous citations in prominent radiological journals. Her studies on abdominal and genitourinary radiology are referenced by other researchers and clinicians, indicating the high regard in which her work is held. This academic recognition is a testament to the quality and relevance of her research contributions.

LEGACY AND FUTURE CONTRIBUTIONS ON ENDOMETRIUM CANCER

  • Dr. Aydın’s legacy in the field of radiology is characterized by her dedication to advancing medical imaging and improving patient care. Looking ahead, she is poised to continue her impactful research and clinical work, with a focus on innovative imaging techniques and their applications in abdominal and genitourinary radiology. Her future contributions are expected to further enhance the understanding and practice of radiology, benefiting both the medical community and patients.

OTHER IMPORTANT TOPICS

TEACHING AND MENTORSHIP

  • In addition to her research and clinical responsibilities, Dr. Aydın is deeply committed to teaching and mentoring the next generation of radiologists. Her role at the University of Health Sciences allows her to shape the education and training of medical students and residents, ensuring the continued growth and development of the field.

COLLABORATIVE PROJECTS

  • Dr. Aydın actively engages in collaborative projects with other institutions and researchers. These collaborations enable the sharing of knowledge and expertise, fostering innovation and improving radiological practices globally. Her collaborative efforts have resulted in several joint publications and research initiatives.

PROFESSIONAL DEVELOPMENT

  • Continuous professional development is a cornerstone of Dr. Aydın’s career. She regularly participates in international conferences, workshops, and training programs to stay abreast of the latest advancements in radiology. This commitment to lifelong learning ensures that she remains at the forefront of her field, providing the highest standard of care to her patients.

 

📊🔬Notable Publication:

Extrapulmonary Tuberculosis: An Old but Resurgent Problem

  • Authors: Baykan, A.H., Sayiner, H.S., Aydin, E., Inan, I., Erturk, S.M.
    Journal: Insights into Imaging
  • Year: 2022

 

Quantitative Analysis of the Olfactory System in COVID-19: An MR Imaging Study

  • Authors: Altunisik, E., Baykan, A.H., Sahin, S., Aydin, E., Erturk, S.M.
    Journal: American Journal of Neuroradiology
  • Year: 2021

 

Primary Breast Tuberculosis: Imaging Findings of a Rare Disease

  • Authors: Baykan, A.H., Sayiner, H.S., Inan, I., Aydin, E., Erturk, S.M.
    Journal: Insights into Imaging
  • Year: 2021

 

Reliability of Real-Time Sonoelastography in the Diagnosis of Supraspinatus Tendinopathy

  • Authors: Aydın, E., Söylev, G.Ö., Muratlı, S.K., Tekindal, M.A., Ağıldere, M.
    Journal: Ultrasound Quarterly
  • Year: 2021

 

Optical Coherence Tomography-Angiography Findings of Prediabetic Patients

  • Authors: Emre, S., Altin, C., Ulusoy, M.O., Aydin, E.
    Journal: Oman Journal of Ophthalmology
  • Year: 2024

Prof Dr. Nives Pećina-Šlaus – Cancer Genetics – Best Researcher Award

Posted on by Pencis

Prof Dr. Nives Pećina-Šlaus - Cancer Genetics - Best Researcher Award

Department of Biology School of Medicine University of Zagreb - Croatia

AUTHOR PROFILE 

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Nives Pecina-Slaus embarked on her academic journey at the University of Zagreb, where she earned her Bachelor's and Master's degrees in Biology in 1990 and 1992, respectively. Her scholarly pursuits culminated in a Ph.D. in the field of molecular oncology from the Medical School at the University of Zagreb in 1998. During her education, she underwent training at prestigious institutions including the Cold Spring Harbor Laboratory in New York and Georgetown University in Washington DC, USA.

PROFESSIONAL ENDEAVORS

Pecina-Slaus's professional career is distinguished by her role as a tenured professor at the Department of Biology and Head of the Laboratory of Neuro-oncology at the Croatian Institute for Brain Research within the School of Medicine at the University of Zagreb. She has served as the principal investigator on seven scientific projects, demonstrating her leadership in the field. Moreover, her research has yielded significant contributions, with over 100 publications to her credit, including scientific papers, book chapters, and a book. Her primary research interests encompass cancer genetics, the Wnt signaling pathway, epithelial to mesenchymal transition, brain tumorigenesis, tumor suppressor genes, and oncogenes.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Pecina-Slaus's work has contributed extensively to our understanding of neuro-oncology and related fields. Her research has shed light on crucial mechanisms underlying cancer development and progression, particularly in the context of brain tumors. Through her numerous publications, she has disseminated valuable insights into cancer genetics, signaling pathways, and tumor microenvironment dynamics. Her expertise extends to mentorship, where she has guided numerous students in their theses.

IMPACT AND INFLUENCE

Pecina-Slaus's contributions have garnered widespread recognition in the scientific community, as evidenced by her invitations to speak at 25 meetings. Furthermore, her work has had a substantial impact on the academic community, as reflected in her impressive citation metrics. With over 2600 citations on Google Scholar and notable indices on Scopus and Web of Science, she has established herself as a respected authority in her field.

ACADEMIC LEGACY AND FUTURE CONTRIBUTIONS

Pecina-Slaus's legacy is marked by her prolific research output, mentorship of students, and editorial roles in esteemed scientific journals. Her dedication to advancing knowledge in neuro-oncology and related disciplines has earned her numerous awards and accolades, including recognition from the Croatian Medical Association and the Academy of Medical Sciences. Moving forward, she is poised to continue making significant contributions to the field through her research, teaching, and editorial activities, further solidifying her position as a leader in neuro-oncology research.

NOTABLE PUBLICATIONS

Glioma Stem Cells—Features for New Therapy Design. 2024

Genetics in ophthalmology: molecular blueprints of retinoblastoma. 2023 (3)

Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment. 2023 (6)

Different Approaches to Study Molecular Blueprint and Biological Behavior of Brain Tumors: Editorial to the Special Issue “Advances in Molecular Genetics of Brain Tumors”. 2023

Bilateral Meningioma: A Case Report and Review of the Literature. 2022 (2)

 

 

Prof Dr. Zsuzsanna Suba – Cancer Genetics – Distinguished Cancer Treatment Innovation Award

Posted on by Pencis

Prof Dr. Zsuzsanna Suba - Cancer Genetics - Distinguished Cancer Treatment Innovation Award

National Institute of Oncology, Budapest - Hungary

AUTHOR PROFILE

Orcid

EARLY ACADEMIC PURSUITS

Prof. Dr. Zsuzsanna Suba began her academic journey at Semmelweis University in Budapest, where she earned both MD and PhD degrees. During this time, she also obtained postdoctoral board certification in pathology, laying the foundation for her expertise in cancer research.

PROFESSIONAL ENDEAVORS

After completing her postdoctoral certification, Suba delved into cancer research, initially focusing on the effects of chemotherapeutic agents on cell cultures and experimental animals. Later, she expanded her expertise by gaining scientific graduations in oral pathology and habilitation at the Institute of Oral and Maxillofacial Surgery, Semmelweis University, as well as a certification in oral pathology from the University of Sheffield.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Suba's research has been multifaceted, covering various aspects of cancer development and therapy response. She led a working group that investigated the osseointegration of biomaterials in oral and periodontal tissues and explored metabolic and hormonal aspects of oral cancer. Notably, her research identified insulin resistance and estrogen deficiency as risk factors for oral cancer.At the National Institute of Oncology in Budapest, Suba delved into the correlations among hormonal imbalance, metabolic disorders, and genomic instability in female breast cancer patients.

IMPACT AND INFLUENCE

Suba's work has significantly contributed to our understanding of cancer development and treatment response, particularly in oral and breast cancer. Her identification of novel risk factors and exploration of hormonal and metabolic influences have informed both clinical practice and further research in the field.

ACADEMIC CITATIONS

Suba's contributions to cancer research have garnered recognition and citations within the academic community, solidifying her reputation as an expert in clinical cancer genetics and pathology.

LEGACY AND FUTURE CONTRIBUTIONS

As a professor emeritus, Suba continues to shape the future of cancer research, advocating for new strategies that prioritize DNA stabilization in cancer cases. Her emphasis on supportive cancer care underscores the importance of innovative approaches to enhance patient outcomes and quality of life.

NOTABLE PUBLICATIONS

DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care. 2024

Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations. 2020 (7)

 

Prof. Apostolos Zaravinos – Cancer Genetics – Excellence in Research

Posted on by Pencis

Prof. Apostolos Zaravinos - Cancer Genetics - Excellence in Research

European University Cyprus - Cyprus

Author Profile

Google Scholar

Orcid

Scopus

EARLY ACADEMIC PURSUITS

Dr. Apostolos Zaravinos began his academic journey with a B.Sc. in Molecular Biology from the Department of Biology at the University of Crete in 2004. He further pursued his passion for medicine by obtaining his Ph.D. in Medicine from the Medical School of the same university in 2008. These foundational academic pursuits laid the groundwork for his subsequent research and professional endeavors in the field of cancer genetics and molecular biology.

PROFESSIONAL ENDEAVORS

After completing his Ph.D., Dr. Zaravinos embarked on a series of professional roles that enriched his expertise and contributed to the scientific community. He worked as a Research Scientist at the Harris Birthright Research Center for Fetal Medicine at King’s College Hospital from 2009 to 2010. Subsequently, he performed postdoctoral research in Cancer Genetics at the Molecular Medicine Research Center of the University of Cyprus from 2011 to 2013. He further honed his skills in Immunogenetics and Cancer Genetics during his postdoctoral training at the Department of Laboratory Medicine of the Karolinska Institute from 2013 to 2015.In 2015, Dr. Zaravinos was appointed as an Assistant Professor of Cancer Genetics at the European University Cyprus. He was promoted to the rank of Associate Professor in 2019. He also served as an Associate Professor of Genetics at the Department of Basic Medical Science, College of Medicine (CMED) at Qatar University from 2020 to 2021. These academic positions allowed him to mentor students, lead research projects, and contribute to the advancement of cancer genetics and immunogenetics.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Dr. Zaravinos' research contributions are significant and multifaceted. His primary research aim is to achieve an advanced understanding of carcinogenesis by investigating interactions between genes. He is particularly interested in Cancer Immunogenetics and aims to elucidate how the tumor microenvironment relates to different aspects of tumor biology. His research has focused on examining the immune landscape of inflamed tumors, including colorectal cancer and skin melanoma, using next-generation sequencing approaches.

IMPACT AND INFLUENCE

Dr. Zaravinos has made a substantial impact on the field of cancer genetics and immunogenetics. He has authored over 125 original research articles and 7 book chapters, demonstrating his prolific research output. His work has been cited over 3,600 times, with an h-index of 35, as documented on Scopus. His research findings have contributed to the scientific community's understanding of carcinogenesis, tumor immunology, and the tumor microenvironment.

ACADEMIC CITES

Dr. Zaravinos' research has garnered significant attention and recognition in the scientific community, as evidenced by his high citation count and h-index. His publications have been cited over 3,600 times, highlighting the impact and relevance of his research in the field of cancer genetics and immunogenetics.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Zaravinos' legacy in the field of cancer genetics and immunogenetics is characterized by his groundbreaking research, mentorship, and contributions to scientific literature. His work has paved the way for future research endeavors aimed at understanding carcinogenesis, tumor immunology, and the tumor microenvironment. As a dedicated researcher and educator, Dr. Zaravinos continues to inspire and influence the next generation of scientists, leaving a lasting impact on the field of cancer genetics and molecular biology. His future contributions are eagerly anticipated as he continues to explore new avenues in cancer research and mentor emerging scientists in the field.

NOTABLE PUBLICATIONS

Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1. 2024

Peptide absent sequences emerging in human cancers. 2024

Immune Cytolytic Activity and Strategies for Therapeutic Treatment. 2024

Strand asymmetries across genomic processes. 2023

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies. 2023 (3)

 

Dr. Takashi Takeshita – Cancer Genetics – Best Researcher Award

Posted on by Pencis

Dr. Takashi Takeshita - Cancer Genetics - Best Researcher Award

Kumamoto City Hospital - Japan

Author Profile

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Takashi Takeshita initiated his academic journey by obtaining a Medical Doctorate (M.D.) from the National Defense Medical College, Saitama, Japan, in 2005. He furthered his education by earning a Ph.D. from St. Marianna University School of Medicine, Kanagawa, Japan, in 2012. These early academic pursuits established the foundation for his future contributions to cancer genetics.

PROFESSIONAL ENDEAVORS

Since 2022, Takashi Takeshita has been serving as the Chief of Breast and Endocrine Surgery at Kumamoto City Hospital, Japan. His professional journey is marked by significant achievements, including the receipt of several prestigious awards: the 2017 Research Award from the Japanese Breast Cancer Society, the 2017 Research Award from the Japanese Society of Medical Oncology, the 2018 Young Investigator’s Award from the Japan Surgical Society, and the 2018 Excellent Presentation Award from the Japanese Breast Cancer Society.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS 

Takashi Takeshita's 19-year research career spans various research institutes, showcasing a robust expertise in cancer genetics. His focus includes genetic analysis of clinical specimens, utilizing techniques such as digital PCR for tumor tissue and plasma DNA, immunohistochemical staining, automated assay robot operation, and more. His experience in large-scale cell culture and comprehensive knowledge of molecular biology, pharmacology, and analytical methods underscore his dedication to advancing cancer research.

IMPACT AND INFLUENCE

The awards received by Takashi Takeshita, coupled with his role as the Chief of Breast and Endocrine Surgery, affirm his impact and influence in the medical field. His leadership and contributions to cancer genetics, particularly in breast cancer research, position him as a prominent figure. His membership in esteemed academic societies, including the Japanese Breast Cancer Society, Japan Surgical Society, Japanese Cancer Association, Japanese Society of Medical Oncology, and the American Association for Cancer Research, further reflects his influence on a global scale.

ACADEMIC CITES

Takashi Takeshita's involvement in renowned academic societies and receipt of research awards suggest that his work likely receives recognition and citations within the scientific community. His expertise in genetic analysis and clinical research contributes to the advancement of cancer genetics literature.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

Takashi Takeshita's legacy is built upon a foundation of excellence in cancer genetics, marked by numerous awards and leadership roles. His dedication to advancing breast and endocrine surgery and his contributions to genetic analysis techniques set the stage for a lasting impact. Looking ahead, Takeshita is poised to continue making significant contributions to cancer genetics, shaping the future landscape of research in breast cancer and beyond. His membership in international societies signifies a commitment to global collaboration and further advancements in cancer research.

NOTABLE PUBLICATIONS

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing. 2024

Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment. 2023

Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer. 2023 (5)

Fulvestrant plus palbociclib in advanced or metastatic hormone. 2023 (2)

High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment. 2023